Recent news on Evoclin

Stiefel Laboratories Moves to Solidify, Enhance Its Leadership ...  -  Apr 23, 2007
PR Newswire (press release),Some of the newest and best- known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%;

Stiefel Laboratories Moves to Solidify, Enhance Its Leadership ...  -  Apr 23, 2007
PharmaLive.com (press release),Some of the newest and best- known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%;

Stiefel Laboratories, Inc. Donates First Dermatology Ward in ...  -  Feb 2, 2007
Drug Newswire (press release),Duac(R) Topical Gel, MimyX(TM) Cream, Olux(R), Brevoxyl(R) Creamy Wash, Oilatum(R), Soriatane(R), Evoclin(TM), Verdeso(TM) and Luxiq(R).

Stiefel Laboratories, Inc. Appoints Richard J. MacKay Vice ...  -  Jan 30, 2007
PharmaLive.com (press release),Some of the best-known brands include Sarna(r), Duac(r) Topical Gel, MimyX(tm) Cream, Olux-E(r), Brevoxyl*Creamy Wash, Oilatum(r), Soriatane(r), Evoclin(r),

Stiefel Laboratories, Inc. Completes Acquisition of Connetics ...  -  Dec 29, 2006
PharmaLive.com (press release),Some of the best-known brands include Sarna(R), Duac(R) Topical Gel, MimyX(TM) Cream, Olux(R), Brevoxyl(R)Creamy Wash, Oilatum(R), Soriatane(R), Evoclin(R),

Stiefel Laboratories, Inc. Completes Acquisition of Connetics ...  -  Dec 28, 2006
Yahoo! News (press release)Some of the best-known brands include Sarna®, Duac® Topical Gel, MimyX(TM) Cream, Olux®, Brevoxyl®Creamy Wash, Oilatum®, Soriatane®, Evoclin®, Verdeso(TM)

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Genetic Engineering News (press release),Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) capsules; Evoclin(R) (clindamycin) Foam, 1%; and Verdeso(TM) (desonide) Foam,

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Business Wire (press release),0.05%; Luxíq ® (betamethasone valerate) Foam, 0.12%; Soriatane ® (acitretin) capsules; Evoclin ® (clindamycin) Foam, 1%; and Verdeso™ (desonide) Foam,

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Genetic Engineering News (press release),Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) capsules; Evoclin(R) (clindamycin) Foam, 1%; and Verdeso(TM) (desonide) Foam,

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Business Wire (press release),0.05%; Luxíq ® (betamethasone valerate) Foam, 0.12%; Soriatane ® (acitretin) capsules; Evoclin ® (clindamycin) Foam, 1%; and Verdeso™ (desonide) Foam,

Connetics Q3 Turns To Loss On Fall In Revenue - Update  09 Nov 2006
Product revenues include Soriatane sales of $10.4 million, OLUX sales of $4.3 million, Evoclin sales of $2.3 million and Luxiq sales of $1.8 million. ... -Trading Markets, Connetics Reports Third Quarter Financial Results  Nov 8, 2006
Third quarter 2006 product revenues include Soriatane® sales of $10.4 million, OLUX® sales of $4.3 million, Evoclin® sales of $2.3 million and Luxíq ... -Business Wire (press release), Connetics Corporation to Merge into Stiefel Laboratories  Oct 24, 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) capsules; Evoclin(R) (clindamycin) Foam ... -Drug Newswire (press release), Connetics Corporation to Merge into Stiefel Laboratories  Oct 23, 2006
...are OLUX® (clobetasol propionate) Foam, 0.05%; Luxiq® (betamethasone valerate) Foam, 0.12%; Soriatane® (acitretin) capsules; Evoclin® (clindamycin) Foam, 1 ... -Yahoo! News (press release) FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to ...  Sep 20, 2006
...to Verdeso, Connetics' VersaFoam-based products are OLUX for scalp dermatoses and non-scalp psoriasis, Luxiq Foam for scalp dermatoses and Evoclin(R) Foam for ... -PharmaLive.com

Connetics Reports Positive Results From Second Phase III Clinical ...  Aug 28, 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) capsules; and Evoclin(R) (clindamycin ... -Genetic Engineering News

Connetics Announces Special Meeting of Stockholders to Approve ...  -  12 Dec 2006
Business Wire (press release),0.05%; Luxíq ® (betamethasone valerate) Foam, 0.12%; Soriatane ® (acitretin) capsules; Evoclin ® (clindamycin) Foam, 1%; and Verdeso (desonide) Foam,

Connetics Reports Positive Results From Second Phase III Clinical ...  29 Aug 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) capsules; and Evoclin(R) (clindamycin ... -PipelineReview.com

Connetics Reports Second Quarter Financial Results  Aug 14, 2006
Second quarter 2006 revenues include Soriatane(R) sales of $16.3 million, OLUX(R) sales of $12.2 million, Evoclin(R) sales of $9.3 million and Luxiq(R) sales ... -Business Wire

Connetics Reports New Option Grants Under Nasdaq Marketplace Rule ...  Aug 7, 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(R) (clindamycin ... -Business Wire

Connetics Announces Extension and Changes in Terms of Convertible ...  Jul 19, 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) capsules; and Evoclin(R) (clindamycin ... -Business Wire



Connetics Reports Preliminary Results for First Quarter 2006 ...  May 3, 2006
...revenues for the first quarter of 2006 were $47.7 million, including Soriatane(R) sales of $19.0 million, OLUX(R) sales of $14.1 million, Evoclin(R) sales of ... - PharmaLive.com

Connetics Names Sunil Patel Vice President, Corporate Development ...  May 9, 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(R) (clindamycin ... - PharmaLive.com





Connetics Provides Information on Securities and Exchange ...  Apr 7, 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) capsules; and Evoclin(R) (clindamycin ... - PharmaLive.com

Connetics Files Citizen Petition for Soriatane With the FDA ...  Apr 3, 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(R) (clindamycin ... - Genetic Engineering News

Insider lawsuit is familiar  Mar 30, 2006
...a vice president involved in drug development and clinical trials with Connetics Corp., a Palo Alto maker of prescription acne medication including Evoclin. ... - San Francisco Chronicle

President leaves PediaMed after sales force sold  Feb 27, 2006
Connetics said the PediaMed group would begin selling Evoclin (clindamycin) Foam, 1 percent, a topical treatment for acne, and Luxiq (betamethasone valerate ... - Cincinnati Business Courier,

Connetics Names Freddie Park Vice President, Intellectual Property ...  Feb 6, 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(TM) (clindamycin ... - Genetic Engineering News,

Connetics Reports Fourth Quarter Revenues of $41.3 Million and EPS ...  Jan 31, 2006
Fourth quarter 2005 product revenues included OLUX(R) sales of $14.7 million, Soriatane(R) sales of $13.6 million, Evoclin(TM) sales of $6.9 million and Luxiq(R ... - Genetic Engineering News

Connetics Names Freddie Park Vice President, Intellectual Property ...  Feb 6, 2006
...are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(TM) (clindamycin ... - Genetic Engineering News

Connetics Acquires PediaMed Sales Organization; Enters Pediatric ...  Jan 10, 2006
...a one-month training program that begins with the Connetics' national sales meeting in early February, the group will begin selling Evoclin(TM) (clindamycin ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional